Biotech stocks have been extremely popular among investors in 2020. Over the past year, the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB), an industry indicator, has returned over 33%, compared to the S&P 500's 14% return during the same period. It's clear that a lot of eyes are on producers of testing supplies, drugs, and vaccines for the coronavirus.
The extraordinary attention paid to coronavirus stocks has left other top-notch biotechs out of the spotlight. I think that many of them are undervalued because of it. Let's look at why a blue chip drugmaker focused on rare diseases and a CRISPR gene-therapy developer have the potential to double your money.
Image Source: Getty Images.
Vertex Pharmaceuticals(NASDAQ:VRTX) has become a leader in the treatment of cystic fibrosis. This hereditary disease severely restricts patients' ability to breathe due to abnormally viscous fluid accumulating in the lungs. Vertex's triple-combination cystic fibrosis therapy, Trikafta, improved patients' respiratory volume by 14.3% compared to placebo in clinical trials.
Even though the improvement is arguably a small one, that hasn't stopped the drug from becoming wildly popular in the U.S. and EU. Right now, approximately 50% of 83,000 cystic fibrosis patients in several developed countries are receiving one of Vertex's medications. Vertex also plans to expand Trikafta's label to treat children and infants with cystic fibrosis. For the remaining 10% of patients who require gene therapy to alleviate cystic fibrosis, Vertex has a therapeutic in its pipeline for their use as well.
Thanks to Trikafta, Vertex projects that its 2020 revenue and operating income will surpass $6 billion and $3 billion, respectively. Those numbers are fantastic, considering the company had $4 billion in sales and close to $2 billion in operating income in 2019.
Despite trading at a premium of 10 times revenue, Vertex is wildly profitable. These earnings and its impressive growth trajectory makes its price-to-earnings (P/E) ratio of 22 easier to swallow. As icing on the cake, Vertex has no debt and over $6 billion in cash on its balance sheet.
CRISPR Therapeutics(NASDAQ:CRSP) has already made investors richer with a 235% return over the past year. Right now, it is leveraging its gene-editing technology to help patients overcome hereditary blood disorders such as sickle cell anemia and beta thalassemia. These cause severe, life-threatening deformities in patients' red blood cells and occur in over 360,000 newborns worldwide each year.
The company proposes to alleviate the illnesses by transfusing genetically modified stem cells containing fetal hemoglobin into patients, and having the cells mature into normal adult hemoglobin. During a phase 1/2 interim data release, patients' hemoglobin levels improved to those of healthy adults between five to 18 months after transfusion.
Even better, CTX001, the company's treatment, was well tolerated. The results, although early, are nothing short of incredible as even novel treatments for sickle cell disease cannot go as far as normalizing patients' hemoglobin levels.
However, CRISPR Therapeutics isn't only interested in curing blood disorders. It is also applying its gene-editing expertise to the field of allogeneic T-cell therapy for cancer treatment.
This process involves first programming T-cells' genetic data from healthy donors so they target and kill cancer cells. Afterward, the enhanced cells are mass-produced and stored. They are then custom matched to patients based on their type of cancer mutation.
The technique has much higher efficacy and availability than the more traditional autologous T-cell therapy, which involves extracting T-cells directly from cancer patients, altering their components, and then transfusing them back into the patients. The whole procedure can take up to three weeks and produce only a single course of therapy.
The company's most promising therapeutic candidate in this field is CTX110. In a phase 1 interim data release, 12 patients with late-stage lymphoma received CTX110 transfusions. Out of eight participants who received the higher doses, four of these patients developed a complete response with no serious side effects. A "complete response" is defined as the total elimination of tumor or cancer activity.
Considering that a single novel and effective cancer treatment can have a valuation upward of $10 billion, there is definitely a tremendous amount of potential for CRISPR Therapeutics' pipeline. Furthermore, the company has about $1 billion in cash and equivalents on hand, which is more than enough to offset its $211.3 million in operating and research cash use. CRISPR will surely more than double investors' money again if it develops any functional cure or effective genetic treatments in its clinical trials.
Original post:
2 Biotech Stocks That Could Double Your Money - The Motley Fool
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
- Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell ... - OncLive - December 1st, 2023
- Mitophagy in human health, ageing and disease - Nature.com - December 1st, 2023
- Adult Stem Cells - Stem Cells and the Future of Regenerative Medicine ... - November 29th, 2023
- Navigating The Regulatory Landscape Of Longevity Health Products ... - Mondaq News Alerts - November 29th, 2023
- MS breakthrough could lead to treatments that halt disease's ... - inews - November 29th, 2023
- Reprogramming tissue mechanically to promote wound healing - Phys.org - November 29th, 2023
- Latest Advances in Arthritis Diagnosis and Treatment at American ... - HealthDay - November 29th, 2023
- Sex-associated differences in frequencies and prognostic impact of ... - Nature.com - November 29th, 2023
- Hematologists Dive into the Current Treatment Landscape - OncLive - November 29th, 2023
- Team discovers protein crucial for B cell differentiation and antibodies - Phys.org - November 29th, 2023
- Science Talk - I survived cancer as a child and now I'm working to ... - The Institute of Cancer Research - November 29th, 2023
- First Edition: Nov. 29, 2023 - KFF Health News - November 29th, 2023
- Symptoms: Unilateral Hearing Loss and Tinnitus : The Hearing Journal - LWW Journals - November 29th, 2023
- Mitigation of sepsis-induced acute lung injury by BMSCs | IJN - Dove Medical Press - November 29th, 2023
- A Case of a Constricted Vessel: The Impact of Acute Myeloid ... - Cureus - November 29th, 2023
- Mum brushed off fatigue after having baby but fall sparked deadly diagnosis - The Mirror - November 29th, 2023
- How heritable is the epigenome? - Drug Discovery News - November 29th, 2023
- The Blueprint of Regeneration: Scientists Discover How to Turn Stem Cells Fate - Revyuh - November 27th, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - Marketscreener.com - November 27th, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - PharmiWeb.com - November 25th, 2023
- COVID-19 Pandemic's Adverse Effect on Bone Health in Young ... - HealthDay - November 25th, 2023
- Sickle cell breakthrough - The Indian Express - November 25th, 2023
- Wall thickness analysis method for judging the degree of lower ... - Nature.com - November 25th, 2023
- Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference - Yahoo Finance - November 23rd, 2023
- Disease Transmission and Diagnosis of Zika Virus - Cureus - November 23rd, 2023
- Gene-editing therapy for sickle cell earns conditional approval in UK - Sickle Cell Disease News - November 23rd, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - Newswire - November 21st, 2023
- Efficacy of ADSC-CM in Patients with Telogen Effluvium | SCCAA - Dove Medical Press - November 21st, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - PR Newswire - November 21st, 2023
- The Impact of CAR T Cell Therapy on Managing R/R LBCL - OncLive - November 21st, 2023
- Mansour bin Zayed witnesses inauguration of ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2023 - ZAWYA - November 21st, 2023
- Listeria: Who is most susceptible? What are the Symptoms? What ... - Food Poison Journal - November 21st, 2023
- Scope Of Issued Patents May Be Limited By Prosecution Estoppel ... - Mondaq News Alerts - November 21st, 2023
- Qrons Announces the Addition of Professor Shiri Navon-Venezia to ... - StreetInsider.com - November 21st, 2023
- Financially strapped Athersys raises $10.4M - cleveland.com - November 19th, 2023
- From the India Today archives (2010) | How stem cells can save your life - India Today - November 19th, 2023
- Inactivation of the tumor suppressor gene Apc synergizes with H ... - Science - November 19th, 2023
- The Origins of Multiple Myeloma and Why it Matters - HealthTree For AML - Acute Myeloid Leukemia - November 19th, 2023
- Treatment Considerations With TROP2-Targeted Therapy - OncLive - November 19th, 2023
- Athersys narrows loss, raises $10.4 million during third quarter to ... - The Business Journals - November 17th, 2023
- Who was Dolly the Sheep and what happened to her? The story of ... - BBC Countryfile Magazine - November 17th, 2023
- UK first to approve CRISPR treatment for diseases: what you need to ... - Nature.com - November 17th, 2023
- 1st sickle cell patient to be given therapy restoring fetal hemoglobin - Sickle Cell Disease News - November 15th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - Century - Benzinga - November 13th, 2023
- Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer - Yahoo Finance - November 11th, 2023
- Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in... - November 11th, 2023
- AAO 2023: Paul Runge and his ROP treatments in the Ukraine - Modern Retina - November 11th, 2023
- The Evolutionary Reasons We Are Drawn To Horror Movies and ... - Slashdot - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - GlobeNewswire - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 9th, 2023
- NYU Langone Health Performs World's First Whole-Eye & Partial ... - NYU Langone Health - November 9th, 2023
- BrainStorm to Announce Third Quarter 2023 Financial Results and ... - BioSpace - November 9th, 2023
- Can we cut cost and pain of IVF? Start-up CEO tries out own ... - Genetic Literacy Project - November 9th, 2023
- Jasper Therapeutics Reports Third Quarter 2023 Financial Results ... - BioSpace - November 9th, 2023
- Impaired neural stress resistance and loss of REST in bipolar ... - Nature.com - November 9th, 2023
- Functional genomics and systems biology in human neuroscience - Nature.com - November 9th, 2023
- Trial launched to test CAR T-cell therapy in dogs diagnosed with ... - EurekAlert - November 9th, 2023
- The-Gut's-Lasting-Impact-on-Severe-COVID-19-Immune-Response - Infectious Disease Special Edition - November 9th, 2023
- Emerging Cure for Sickle Cell on its Way to FDA Approval, Carries ... - Dallasweekly - November 7th, 2023
- The science works, but will we pay for it? - Irish Medical Times - November 7th, 2023
Recent Comments